Oral administration of the OKT3 antibody increases CD4+LAP+ and CD4+CD25+LAP+ Tregs populations, elevates serum TGF-β, significantly reduces AST, and improves insulin resistance and hepatic injury (122). Here, TGFB1 is linked to Insulin resistance.